Trials / Completed
CompletedNCT02450539
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib | Administered orally |
| DRUG | Docetaxel | Administered IV |
Timeline
- Start date
- 2015-08-06
- Primary completion
- 2017-03-31
- Completion
- 2020-07-29
- First posted
- 2015-05-21
- Last updated
- 2021-08-13
- Results posted
- 2018-06-26
Locations
51 sites across 13 countries: United States, Australia, France, Germany, Hungary, Italy, Poland, Romania, Russia, South Korea, Spain, Taiwan, Ukraine
Source: ClinicalTrials.gov record NCT02450539. Inclusion in this directory is not an endorsement.